Therefore, the combination of cationic liposome conjugated gp100 and CpG-ODN with anti PD-1 monoclonal antibody can be regarded as a potential therapeutic approach for the enhancement of immunotherapy in melanoma. The gene discussed is PDCD1; the disease is melanoma.